Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Approval Standards, FDA Reputation At Stake With Avastin Hearing, NEJM Authors Say

This article was originally published in The Pink Sheet Daily

Executive Summary

In separate perspective pieces in the New England Journal of Medicine, Boston academics criticize the 2008 approval of bevacizumab's breast cancer claim based on progression-free survival and warn the agency's credibility will be undermined if the claim is not withdrawn.

You may also be interested in...



CDER Attacks Genentech's Plans For New Confirmatory Trial At Avastin Hearing

Proposed study of bevacizumab in first-line metastatic breast cancer is unlikely to substantiate the magnitude of progression-free survival benefit seen in the E2100 trial, Division of Biologic Oncology Products Director Patricia Keegan says.

CDER Attacks Genentech's Plans For New Confirmatory Trial At Avastin Hearing

Proposed study of bevacizumab in first-line metastatic breast cancer is unlikely to substantiate the magnitude of progression-free survival benefit seen in the E2100 trial, Division of Biologic Oncology Products Director Patricia Keegan says.

Less Than Half Of ODAC Members Will Participate In Avastin Hearing

The "jury" for FDA's June 28-29 hearing on Avastin's breast cancer indication will consist of only six voting participants, five of whom previously called for the claim's withdrawal.

Related Content

Topics

UsernamePublicRestriction

Register

PS072424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel